SGLT2 INHIBITORS REDUCE MAJOR ADVERSE CARDIOVASCULAR EVENTS IN TYPE 2 DIABETIC PATIENTS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Shamna Haris,Sukhchain Singh,Sana Chaudhary,Mahwash Siddiqui,Onyambu Steve Biko,Sarabjeet Singh,Haris Hamsakutty,Sandeep Khosla,Rohit Arora

SGLT2 INHIBITORS REDUCE MAJOR ADVERSE CARDIOVASCULAR EVENTS IN TYPE 2 DIABETIC PATIENTS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

2018

Shamna Haris
Sukhchain Singh
Sana Chaudhary
Mahwash Siddiqui
Onyambu Steve Biko
Sarabjeet Singh
Haris Hamsakutty
Sandeep Khosla
Rohit Arora

The association between sodium-glucose co transporter 2 (SGLT2) inhibitors and Major Adverse Cardiovascular Events in individuals with type 2 diabetes remain uncertain. This meta-analysis aimed to evaluate the cardiovascular outcomes of FDA approved SGLT2 inhibitors for treatment of diabetes

Keywords:

Randomized controlled trial
Diabetes mellitus
Type 2 diabetes
Internal medicine
Cardiology
Medicine
Meta-analysis
cardiovascular outcomes

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations